
News|Articles|October 2, 2026
5 Psychiatry Headlines You Missed in September 2026
Author(s)Chelsie Derman
Fact checked by: Tim Smith
Here, we review the top psychiatry news in September 2026, from DT120's second Breakthrough Therapy designation to the FDA psychedelic hearing.
Advertisement
Advertisement
September brought regulatory and research momentum for psychedelic therapies in psychiatry. The US Food & Drug Administration (FDA) granted DT120 (lysergide) orally disintegrating tablet (ODT) a second Breakthrough Therapy designation, this time in
Related to this article

Compass Pathways completed its NDA for COMP360 based on 2 phase 3 trials and a phase 2b study with more than 1000 participants with highly chronic TRD.

Dexmedetomidine sublingual film is the first FDA-approved at-home option for acute agitation, based on the phase 3 SERENITY at-home trial.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss tubeless Mobi's FDA clearance, CVS Caremark's CGM formulary shift, and a transmitter-free implant.

Aficamten's label now includes MAPLE-HCM data, in which aficamten monotherapy improved peak VO2 by 2.3 mL/kg/min more than metoprolol at 24 weeks.

Hiddo Heerspink, PharmD, PhD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack finerenone’s FIND-CKD data in FSGS.

Lesley Inker, MD, MS, joins Brendon Neuen, MBBS, PhD, to unpack GFR slope and hierarchical composite endpoints in glomerular disease trials.
Advertisement
Advertisement

